Track topics on Twitter Track topics that are important to you
225 Gateway Boulevard
South San Francisco
United States of America
Phone: 415 635 1500
Fax: 650 866 7204
FibroGen has completed enrolling patients in a Phase lll trial programme that aims to evaluate the use of roxadustat for...Read More... The post FibroGen completes enrolment in Phase lll programme of ...
FibroGen's pamrevlumab, which is indicated to treat patients with locally advanced, unresectable pancreatic cancer, was given -More-
Aktionäre der Hot-Stocks Galapagos und Fibrogen haben nachrichtenarme Wochen verkraften müssen. Dank erfreulicher Studiendaten ist die Lethargie nun beendet - beide Papiere nehmen wieder Fahrt auf ....
FibroGen's pamrevlumab, being developed to treat patients with idiopathic pulmonary fibrosis, was granted fast-track designat -More-
FibroGen (NASDAQ:FGEN), a biopharmaceutical company, today announced the completion of patient enrollment in the Phase 3 studies supporting the U.S. new drug application (NDA) submission for roxadusta...
SAN FRANCISCO, June 04, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a biopharmaceutical company, today announced that management will participate in a Fireside Chat at the Jefferies 2018...
Pamrevlumab Data to be Presented at ATS 2018 and ASCO 2018 Roxadustat U.S. Phase 3 Clinical Studies on Track to Readout in Fourth Quarter 2018Conference Call Today at 5:00 p.m. Eastern Time/2:0...
Roxadustat U.S. Phase 3 Topline Clinical Data Readout on Track for Fourth Quarter of 2018 Feedback from FDA on Pamrevlumab Pivotal Programs in IPF and in Locally Advanced Unresectable Pancreatic Ca...
Single compassionate use subject is an 83 year old woman with a history of lymph node positive breast cancer and recently diagnosed pancreatic cancer in May. With an Eastern Cooperative On...
- Patients with Motor Neurone Disease (MND) admitted to Lane Fox Unit /Royal Brompton Hospital and/or reviewed in Lane Fox Unit /Royal Brompton Hospital clinics and/or outreach ...
FibroGen, Inc. is a biotechnology-based drug discovery company using its expertise in the fields of tissue fibrosis, connective tissue growth factor (CTGF), and hypoxia-inducible ...
Extracellular matrix biology to discover and develop innovative therapies for fibroproliferative disorders - organ fibrosis, tissue repair and regeneration.
We have published hundreds of Fibrogen news stories on BioPortfolio along with dozens of Fibrogen Clinical Trials and PubMed Articles about Fibrogen for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Fibrogen Companies in our database. You can also find out about relevant Fibrogen Drugs and Medications on this site too.